- Display 30 Products per page
Published: June 1, 2006 | Price: $995.00 – $5,990.00
This report focuses on the specific needs and market applications of the critical care pharmaceuticals market, the options presented by the market, the factors associated with strategic market development, and prospects for the future. The major indications for critical care are discussed as well as the range of pharmaceutical products used in the critical care environment. The strategic market characteristics of the critical care pharmaceuticals market are also discussed. The trends —- cost-containment programs, restricted formulary acceptance, clinical pharmacy, and...Published: April 1, 2005 | Price: $3,500.00 – $7,000.00
The current market for diabetes products is large and growing. Both monitoring and therapeutic products have an excellent market outlook. Diabetes markets have long had major areas of unmet need, and that has not changed during the past several decades. In fact, the number of diabetic patients, especially in the United States, will increase at an accelerating rate over the next 20 years. With the recognition of diabetes as a public health issue of increasing importance, greater pressure will be...Published: March 1, 2007 | Price: $3,500.00 – $7,990.00
The market for diabetes-related products is huge and continuing to grow. However, it is not the same market as it was just 3 years ago. New trends in care, new products (both therapeutic and diagnostic), new approaches to long-term complications, and changing public health priorities along with geographic variations are shifting the sands of opportunities in diabetes care. This comprehensive re-evaluation of the major world market for diabetes monitoring and therapeutic products provides in-depth data and analysis including: Detailed epidemiology...Published: April 1, 2005 | Price: $1,995.00 – $3,990.00
This timely overview of direct to consumer (DTC) pharmaceutical marketing examines the numerous issues surrounding DTC practices and markets, using industry and consumer publications as well as interviews with industry experts. The topics examined include: DTC marketing spending by product, DTC marketing spending by company DTC marketing spending by media channel The ROI debate on the cost-effectiveness of DTC marketing expenditures Arguments for and against DTC marketing by its proponents and critics DTC marketing regulations in the U.S. and selected...Published: February 1, 2007 | Price: $2,995.00 – $4,990.00
Fueled by the promise of needle-free mechanisms for vaccine distribution and other pharmaceutical uses, the implantable/injectable drug delivery market is growing rapidly. The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to continued growth. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products. The implantable/injectable delivery drug market is a expected to grow to over $12 billion by 2010. Kalorama’s Drug Delivery Markets. Edition...Published: March 1, 2007 | Price: $2,495.00 – $4,990.00
The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality. The pulmonary drug delivery market reached $25.5 billion in 2006 and is expected to experience high steady growth in the next five years. Contributing to growth are new technologies such as dry powder inhalers...Published: April 1, 2007 | Price: $2,495.00 – $4,990.00
New biological treatments are being developed at a record pace, but their potential could be compromised by a significant obstacle: the delivery of these drugs into the body. Pharmaceutical delivery is now nearly as important as product. Kalorama's Drug Delivery Markets Series covers these new systems. The fourth volume of this series, Kalorama's Drug Delivery Markets, Vol. IV: Transdermal and Transmucosal Drug Delivery is a complete overview of a delivery mechanism that offers some advantages: low pain, infection risk, fewer...Published: September 1, 2009 | Price: $2,995.00 – $5,990.00
With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets. Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. This report looks at that trend and reports...Published: July 1, 2000 | Price: $995.00 – $5,990.00
Since our last edition of this report in 2007, the oral drug delivery market is the largest segment of the drug delivery market, and there’s no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, and seeking to tap into the growing elderly population that requires products with a level of ease-of-use and cost benefit, it’s no surprise that the oral drug delivery market is a...Published: April 1, 2007 | Price: $4,995.00 – $9,990.00
Novel pharmacological and biological approaches to disease are calling for novel systems of delivering therapies. This has focused attention on the market for drug delivery systems and the pharmaceuticals that are sold along with those technologies. Kalorama's Drug Delivery Systems focuses on these technologies. This offer is for the entire 4 volumes of Kalorama's 2nd edition of its Drug Delivery Markets series, covering all major types, including: Oral Delivery Implantable/Injectable Pulmonary Transdermal/Transmucosal While oral delivery remains the most popular and...Published: November 7, 2003 | Price: $746.00 – $1,492.00
Over the past three years, Kalorama Information's analysts have studied drug delivery markets from several angles. In 2001 and 2002, we published a 5-volume series on drug delivery technology, each volume devoted to a route of administration: Volume I: Oral Drug Delivery Volume II: Injectable and Implantable Drug Delivery Volume III: Pulmonary Drug Delivery Volume IV: Transdermal and Transmucousal Drug Delivery Volume V: Advanced Drug Delivery This series segmented the market by technology and included an innovative analysis that estimated...Published: October 1, 2007 | Price: $995.00 – $1,990.00
It can be said that pharmaceutical companies face a 'new era.' in the coming years. Old strategies will not produce the same results. A wave of generic competition is poised to affect most brands. Drug companies have had to cut research budgets, leading to a dearth of new products on the market. This means there is very little margin for error in the pricing decision. Drug pricing is one of the key levers that determine the profitability of a drug...Published: April 1, 2003 | Price: $1,875.00 – $3,750.00
Each year in the United States, more than 500,000 people with coronary artery disease are treated with percutaneous transluminal coronary angioplasty (PTCA). Unfortunately, restenosis occurs within three to six months in 40% to 50% of PTCA patients due to either thrombosis or abnormal tissue growth. As a result, restenosis constitutes the major limitation to the effectiveness of PTCA. To improve on this condition, medical science created stents in an attempt to keep coronary arteries open. However, one of the early...Published: June 1, 2004 | Price: $2,995.00 – $5,990.00
Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to creep in: HTS and UHTS have not lived up to their hype. R&D productivity is not improving, in fact it may be declining. In the...Published: June 1, 2007 | Price: $1,990.00 – $6,990.00
Toxicity is a crucial parameter that is measured throughout the drug development process. Toxic side-effects are one of the most common reasons drug candidates fail. Toxicity can be a factor of dose, the form in which the drug is administered, and the time of exposure before elimination. Patient responses also differ widely, depending on their age and metabolism and other products in the patient’s system may augment the effect of the drug. Just twenty years ago, toxicology was something that...Published: September 12, 2012 | Price: $3,995.00 – $7,990.00
Early toxicology testing is emerging as one of the mostsignificant areas of drug discovery. Toxicity is no longer something that can be left to the development stage, or just a small part of ADMET. Toxicity determinations are an integral part of all aspects of drug discovery & development. This report, Early Toxicology Markets and Approaches, focuses on markets for early toxicology testing services. The objective of this report is to focus the reader’s attention on the issues and opportunities related...Published: November 1, 2008 | Price: $195.00 – $995.00
Often what separates successful marketing from bad is good competitive intelligence. This is true in life sciences as much as other industries. Many companies approach CI in a way that is unplanned, indirect and harmful to their business. But how does one know if they are conducting their company's CI in the best way? If you are trying to determine how to use competitive intelligence better, if you are attempting to judge your efforts compared to companies that have been...Published: February 1, 2004 | Price: $3,500.00 – $7,000.00
Immunologic approaches to cancer therapy are not only increasing in reputation and number, but the market for these products is increasingly becoming a reality. Vaccines are in the forefront of this approach to cancer, and the handful of cancer vaccine products currently on the market for bladder, colon, and skin cancer are soon to be joined by many more with indications for more wide-spread forms, including lung, breast, ovarian, prostate, leukemia, and others. This new study from Kalorama discusses the...Published: September 1, 2010 | Price: $1,500.00 – $3,000.00
Kalorama has been researching and examining the development of cancer vaccines for seven years. In April 2010, the cancer vaccine market experienced one of the biggest achievements in the therapeutic vaccine treatment of cancer—the approval of the prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was merely a speculative area just one decade ago. Even with achievements for some companies, numerous vaccines with apparently strong...Published: November 1, 2008 | Price: $3,995.00 – $7,990.00
It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products. There are several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming...Published: November 1, 2010 | Price: $995.00 – $3,000.00
The European vaccines market has demonstrated growth even through tough economic times. This has mainly been due to the introduction of vaccines in untapped disease markets and government’s acceptance and willingness to pay for new products. This has encouraged market participants to increase spending in research and development. This report, European Vaccine Markets, examines the market for vaccines used in humans for various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable;...Published: August 1, 2007 | Price: $995.00 – $1,990.00
The unrecognized importance, danger and costs of hepatitis in the 21st century cannot be understated or underestimated. The impact of the disease on world society is highly significant and now presenting a major crisis in public health circles. In his exhaustive analysis of the potential diagnosis, screening and therapeutic markets for hepatitis, Ken Krul, PhD. advises companies to think on a global basis. In this study, Global Hepatitis Strategies Krul examines the potential market, epidemiology (hepatitis patient trends) and technology...Published: January 23, 2018 | Price: $3,995.00 – $7,990.00
Global Over-the-Counter (OTC) Drug Markets Global Over-the-Counter (OTC) Drug Markets discusses the world and regional OTC markets, including information on the following: world OTC drug market revenues: 2017 to 2023; top twenty OTC drug markets, country market share (%), 2017 (United States, Japan, China, Germany, France, India, Brazil, Russia, United Kingdom, Australia, Mexico, Canada, Italy, Spain, Poland, Turkey, Argentina, Venezuela, South Africa, Saudi Arabia, rest of world); and world OTC drug market revenues, markets by product segment, 2017 to 2023...Published: June 1, 2007 | Price: $995.00 – $1,990.00
The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles. As illustrated by Kenneth G. Krul, Phd., in Kalorama Information's Global Tuberculosis Strategies, there are abundant opportunities for diagnostic and pharmaceutical companies in combating the global tuberculosis threat. As the author details, there are primarily three focal...Published: March 1, 2004 | Price: $3,500.00 – $7,000.00
Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or blocks the ability of cells to divide and multiply. Blood and tissue growth factors have become exciting targets for compounds intended to inhibit or slow the mechanisms involved in their function or growth. This report highlights the research into, and the current and potential key world markets for, products that...Published: October 1, 2003 | Price: $2,625.00 – $5,250.00
Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or, in some cases, blocks the ability of cells to divide and multiply. The nature and mode of action of these substances have made them of great interest in various therapeutic areas for which efficacy and specificity must go hand in hand. This report analyzes the world markets for growth factors,...Published: May 1, 2010 | Price: $500.00 – $2,400.00
The H1N1 flu epidemic created a public health emergency in 2009. It also created an opportunity for vaccine manufacturers to demonstrate that working with governments of the US and countries around the world, they could manufacture and distribute a vaccine for the virus strain that may have had an impact in reducing cases and deaths. Who were the companies that performed best in this market? How did goverment contracts play out? Most importantly, what are lessons for future pandemic and...Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and ethical pressures, geopolitical factors, and evolving marketplace disruptions. For the development of a coherent strategy in this therapeutic area, companies must clearly focus on three...Published: October 1, 2008 | Price: $2,995.00 – $6,995.00
The strategic concept of HIV/AIDS diagnosis and therapy is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS diagnostics and therapeutics, companies must think on a global basis. In addition to the basic pathology and complications of HIV/AIDS, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (HIV/AIDS patient trends) and technology. In his report HIV Markets for...Published: July 19, 2018 | Price: $4,500.00 – $9,000.00
In Vitro Toxicology In Vitro Toxicology analyses global in vitro toxicity testing markets and various market segments with the objective to identify the important market trends that will bring further growth in this market. The study aims to derive crucial insights that will benefit all the major stakeholders of the industry in developing strategic business plans based on these emerging trends. The report provides market size and growth trends for various toxicity endpoint segments for 2018-2023, including ADME-Tox; cytotoxicity; genotoxicity;...